Comparative Pharmacology
Head-to-head clinical analysis: ARZERRA versus DTIC DOME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARZERRA versus DTIC DOME.
ARZERRA vs DTIC-DOME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Dacarbazine is an alkylating agent that forms methyltriazenoimidazole carboxamide, causing cross-linking of DNA and inhibition of DNA, RNA, and protein synthesis.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
DTIC 250 mg/m2 IV daily for 5 days every 21-28 days, or 850-1000 mg/m2 IV as a single dose every 21-28 days.
None Documented
None Documented
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Terminal elimination half-life is approximately 5 hours (range 4-7 hours) for parent drug; metabolites exhibit longer half-life (up to 8-12 hours). Clinical context: requires multiple dosing cycles due to short half-life.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Renal (40-60% as unchanged drug and metabolites, primarily 5-aminoimidazole-4-carboxamide); biliary/fecal (minimal, <10%)
Category C
Category C
Antineoplastic, Monoclonal Antibody
Antineoplastic